What does the earlier application of immune-oncology agents mean for urological cancer teams?

Joaquim Bellmunt

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.

Share this video  
Similar topics
Related videos
0:44
Adapting acute oncology services to immunotherapy
Nikki Hunter
1:12
Immunotherapy: changing the landscape of cancer treatment
Jean-Pascal Machiels
2:00
Future therapy options for muscle-invasive bladder cancer
Jeanny Aragon-Ching
1:31
The nurse's perspective on caring for lung cancer patients receiving immunotherapy
Rachel Thomas
3:07
Improving adherence to oral therapies in clinical practice
Cheryl Vidall
Genitourinary Cancer
EAU 2017
Interview
26th March 2017
More from Joaquim Bellmunt
When can checkpoint inhibitors be used to treat urothelial carcinoma?
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals